Literature DB >> 31741334

Immunopathogenesis of HBV Infection.

Jun Wu1, Meihong Han1, Jia Li1, Xiaoli Yang1, Dongliang Yang2.   

Abstract

More than 95% of adult infected with HBV show acute self-limited infection and eventually eliminate the virus. In contrast, about 90% of people exposed to HBV in early childhood develop chronic infection. The specificity of the virus and the host's antiviral immune responses together determine the outcome of HBV infection. It is generally believed that viral genome variation, viral titers, and inhibition of viral components against the host immune system are associated with persistent infection and liver damage. The dysfunction of innate immune cells (NK cells, monocyte/macrophages, NKT cells, etc.) and adaptive immune cells (antigen-presenting cells, T cells, B cells) is a key factor leading to virus clearance failure and liver inflammation. In this chapter, we summarize these viral factors and host factors in acute and chronic hepatitis B and update recent understanding of the immune-tolerant phase and pathological mechanisms associated with age and vertical transmission. This will help us to understand more fully the mechanisms of chronic HBV infection and liver injury and to develop combined treatment strategies of direct antiviral drugs for HBV life cycle and immunomodulators.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31741334     DOI: 10.1007/978-981-13-9151-4_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

1.  Effect of Antiviral Therapy During Pregnancy on Natural Killer Cells in Pregnant Women With Chronic HBV Infection.

Authors:  Fuchuan Wang; Si Xie; Chongping Ran; Hongxiao Hao; Tingting Jiang; Wen Deng; Xiaoyue Bi; Yanjie Lin; Liu Yang; Fangfang Sun; Zhan Zeng; Yao Xie; Minghui Li; Wei Yi
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

Review 2.  Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside.

Authors:  Sheikh Mohammad Fazle Akbar; Mamun Al Mahtab; Sakirul Khan; Osamu Yoshida; Julio Cesar Aguilar; Guillen Nieto Gerardo; Yoichi Hiasa
Journal:  Vaccines (Basel)       Date:  2022-05-10

3.  Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study.

Authors:  Fei Xu; Zhu Zeng; Bing Yan; Yiqi Fu; Yilan Sun; Guangdie Yang; Lingfang Tu; Satoshi Watanabe; Salma K Jabbour; Sara Bravaccini; Francesca Fanini; Jianying Zhou; Yihong Shen
Journal:  Transl Lung Cancer Res       Date:  2021-04

4.  In vitro inhibition effects of hepatitis B virus by dandelion and taraxasterol.

Authors:  Ying Yang; Gaoxiang Ying; Shanshan Wu; Fengtian Wu; Zhi Chen
Journal:  Infect Agent Cancer       Date:  2020-07-06       Impact factor: 2.965

Review 5.  Hepatitis B and circadian rhythm of the liver.

Authors:  Ivana Skrlec; Jasminka Talapko
Journal:  World J Gastroenterol       Date:  2022-07-21       Impact factor: 5.374

6.  Interleukin-35 Suppresses Interleukin-9-Secreting CD4+ T Cell Activity in Patients With Hepatitis B-Related Hepatocellular Carcinoma.

Authors:  Qian Zhang; Lanlan Yang; Siqi Liu; Mengyao Zhang; Zhenjing Jin
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.